These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 20040266

  • 1. Promises and drawbacks of targeting cell cycle kinases in cancer.
    Pentimalli F, Giordano A.
    Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
    [Abstract] [Full Text] [Related]

  • 2. Cyclins and related kinases in cancer cells.
    Malumbres M.
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [Abstract] [Full Text] [Related]

  • 3. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A, Schwartz GK.
    Cancer J; 2000 Sep; 6(4):192-212. PubMed ID: 11038138
    [Abstract] [Full Text] [Related]

  • 4. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA, Pentimalli F, Esposito L, Giordano A.
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [Abstract] [Full Text] [Related]

  • 5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 6. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
    Iavarone A, Massagué J.
    Nature; 1997 May 22; 387(6631):417-22. PubMed ID: 9163429
    [Abstract] [Full Text] [Related]

  • 7. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
    Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R.
    Oncogene; 2003 Nov 13; 22(51):8271-82. PubMed ID: 14614451
    [Abstract] [Full Text] [Related]

  • 8. Kinases as targets in the treatment of solid tumors.
    Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K, Ahmed SS, Stebbing J, Knippschild U.
    Cell Signal; 2010 Jul 13; 22(7):984-1002. PubMed ID: 20096351
    [Abstract] [Full Text] [Related]

  • 9. Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
    Montagnoli A, Moll J, Colotta F.
    Clin Cancer Res; 2010 Sep 15; 16(18):4503-8. PubMed ID: 20647475
    [Abstract] [Full Text] [Related]

  • 10. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO, McInnes C.
    Biochem Pharmacol; 2009 May 15; 77(10):1561-71. PubMed ID: 19167366
    [Abstract] [Full Text] [Related]

  • 11. Targeting protein kinases in cancer therapy: a success?
    Pearson MA, Fabbro D.
    Expert Rev Anticancer Ther; 2004 Dec 15; 4(6):1113-24. PubMed ID: 15606337
    [Abstract] [Full Text] [Related]

  • 12. p27kip1 contributions to cancer.
    Nho RS, Sheaff RJ.
    Prog Cell Cycle Res; 2003 Dec 15; 5():249-59. PubMed ID: 14593719
    [Abstract] [Full Text] [Related]

  • 13. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
    Skladanowski A, Bozko P, Sabisz M.
    Chem Rev; 2009 Jul 15; 109(7):2951-73. PubMed ID: 19522503
    [No Abstract] [Full Text] [Related]

  • 14. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases.
    Touyz RM, Yao G.
    J Cell Physiol; 2003 Dec 15; 197(3):326-35. PubMed ID: 14566962
    [Abstract] [Full Text] [Related]

  • 15. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
    Collins I, Garrett MD.
    Curr Opin Pharmacol; 2005 Aug 15; 5(4):366-73. PubMed ID: 15964238
    [Abstract] [Full Text] [Related]

  • 16. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
    Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL.
    Pharmacol Ther; 2014 May 15; 142(2):258-69. PubMed ID: 24362082
    [Abstract] [Full Text] [Related]

  • 17. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L, Siu KT, Raje N.
    Semin Oncol; 2015 Dec 15; 42(6):788-800. PubMed ID: 26615126
    [Abstract] [Full Text] [Related]

  • 18. Protein kinases: From targets to anti-cancer drugs.
    Cruzalegui F.
    Ann Pharm Fr; 2010 Jul 15; 68(4):254-9. PubMed ID: 20637357
    [Abstract] [Full Text] [Related]

  • 19. Emerging cell-cycle inhibitors for pancreatic cancer therapy.
    Bayraktar S, Rocha Lima CM.
    Expert Opin Emerg Drugs; 2012 Dec 15; 17(4):571-82. PubMed ID: 23126234
    [Abstract] [Full Text] [Related]

  • 20. Targeting cell cycle kinases for cancer therapy.
    de Cárcer G, Pérez de Castro I, Malumbres M.
    Curr Med Chem; 2007 Dec 15; 14(9):969-85. PubMed ID: 17439397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.